Detalles de la búsqueda
1.
Mechanistic pharmacokinetic-pharmacodynamic modeling of BACE1 inhibition in monkeys: development of a predictive model for amyloid precursor protein processing.
Drug Metab Dispos;
41(7): 1319-28, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23584887
2.
Antitumor activity of an allosteric inhibitor of centromere-associated protein-E.
Proc Natl Acad Sci U S A;
107(13): 5839-44, 2010 Mar 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-20167803
3.
Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet.
Neurology;
101(14): e1391-e1401, 2023 10 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37643887
4.
Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease.
Sci Transl Med;
13(593)2021 05 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33980574
5.
Preanalytical approaches to improve recovery of amyloid-ß peptides from CSF as measured by immunological or mass spectrometry-based assays.
Alzheimers Res Ther;
10(1): 118, 2018 11 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-30486870
6.
Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
Alzheimers Res Ther;
10(1): 96, 2018 09 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-30231896
7.
Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics.
Mol Neurodegener;
9: 22, 2014 Jun 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-24902845
Resultados
1 -
7
de 7
1
Próxima >
>>